Lymphoma Clinical Trials in Baltimore

Showing 621-633 of 633 trials

Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia

NCT00105313

For primary objectives, we will determine the MTD and examine clinical responses and immune cell populations to determine an OBD, and describe the safety and tolerability of MEDI-507. For the secondary objectives we will look at the antitumor activity of MEDI 507, PK, serum concentrations, and immunogenicity of MEDI-507, as well as time courses of depletion and recovery of CD2 positive and total T-Cell populations.

LymphomaLeukemiaCancer

MedImmune LLC80 participantsStarted Feb 2005

Los Angeles, California, United States • New Haven, Connecticut, United States • Washington D.C., District of Columbia, United States +8 more locations

UNKNOWNPhase 2< 1 mile

A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status.

NCT00333008

The purpose of this study is to evaluate the feasibility and tolerability of delivering a full dose, on time schedule of dose-dense CDOP-R (cyclophosphamide, doxil, vincristine, prednisone, and rituximab) in NHL.

Diffuse Large B Cell LymphomaLymphoma, Non-Hodgkin

The Alvin and Lois Lapidus Cancer Institute27 participantsStarted May 2006

Baltimore, Maryland, United States • Randallstown, Maryland, United States

COMPLETEDPhase 134 miles

Phase I Study of Intrathecal Topotecan

NCT00001333

The purpose of this study is to determine the qualitative and quantitative toxicity of intrathecal topotecan, a topoisomerase I inhibitor, in patients with meningeal malignancies refractory to conventional therapy (radiation therapy and chemotherapy).

LeukemiaLymphomaMeningeal Neoplasms

National Cancer Institute (NCI)30 participantsStarted Feb 1993

Bethesda, Maryland, United States

Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia

A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status.

Phase I Study of Intrathecal Topotecan

Lymphoma Trials in Other Cities

A Phase I Study of Continuous Infusion Immunotoxin IgG-RFB4-SMPT-dgA in Refractory CD22 Positive B-Cell Lymphoma

A Phase I Study of Infusional Chemotherapy With the P-Glycoprotein Antagonist PSC 833

VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Pegylated Liposomal Doxorubicin Containing Chemotherapy in the Treatment of Older Non-Hodgkin's Lymphoma Patients

Proleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lymphoma.

Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia

Study of Untreated or Transformed Follicular Non-Hodgkin's Lymphoma With Fission-Derived Iodine I 131 Tositumomab

Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma

Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma

Other Conditions in Baltimore